News & Updates

The two-drug regimen dolutegravir plus lamivudine (DTG/3TC) is as good as 3- or 4-drug antiretroviral therapy (ART) regimens at keeping viral load suppressed while helping avoid hepatitis B virus (HBV) reactivation in people living with HIV-1 who have past exposure to HBV but no immunity, according to a post hoc analysis of five phase 3/3b studies.

A substudy of the phase III FLAIR study has found comparable efficacy and pharmacokinetics for cabotegravir (CAB) plus rilpivirine (RPV) via subcutaneous (SC) administration relative to those via intramuscular (IM) gluteal injections among virally suppressed individuals living with HIV-1.

Certain individuals initially testing negative for tuberculosis (TB) by interferon-gamma release assay (IGRA) may later contract the infection and therefore require extended follow-up due to increased risk, as reported in a study from Singapore.

In COVID-19 patients who had mild or no symptoms, the use of 0.05% cetylpyridinium chloride (CPC) and 0.01% on-demand aqueous chlorine dioxide (ACD) mouthwashes did not lead to a reduction in SARS-CoV-2 salivary viral load.